v3.26.1
Segment Information - Schedule of financial information regularly reviewed and used by the CODM (Details) - USD ($)
 3 Months Ended 6 Months Ended
Feb. 21, 2025
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Research and development (excluding stock-based compensation) expense:              
PAH   $ 11,681,245   $ 2,738,794   $ 20,298,800 [1] $ 12,069,638 [1]
Parkinson's disease   0   42,196   0 184,616
Other research and development   227,113   834,142   658,008 1,421,270
Selling, general and administrative (excluding stock-based compensation)   3,796,627   3,366,824   7,403,684 7,027,106
Change in fair value $ (4,435,443) 0   (358,420)   (373,354) (1,523,284)
Stock-based compensation expense   5,346,010   4,208,742   10,905,776 6,250,938
Total costs and expenses   21,050,995   10,832,278   38,892,914 25,430,284
Loss from operations   (21,050,995)   (10,832,278)   (38,892,914) (25,430,284)
Other Income   1,459,764   916,755   2,920,843 1,836,026
Net loss   (19,591,231) $ (16,380,840) (9,915,523) $ (13,678,735) (35,972,071) (23,594,258)
Operating Segment              
Research and development (excluding stock-based compensation) expense:              
Stock-based compensation expense   $ 5,346,010   $ 4,208,742   $ 10,905,776 $ 6,250,938
[1] The six months ended June 30, 2025 figure includes a one-time (non-cash) charge of $7.4 million for the acquired IPR&D related to the CorHepta acquisition.